You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 63 No. 1, January 2006 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Cerebrovascular Disease
 •Neuropathology
 •Stroke
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro–B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease

Duncan J. Campbell, MD, PhD; Mark Woodward, PhD; John P. Chalmers, MD, PhD; Samuel A. Colman, MBios; Alicia J. Jenkins, MD; Bruce E. Kemp, PhD; Bruce C. Neal, MD, PhD; Anushka Patel, MD; Stephen W. MacMahon, PhD

Arch Neurol. 2006;63:60-65. Published online November 14, 2005 (doi:10.1001/archneur.63.1.noc50221).

Background  Patients with stroke or transient ischemic attack are at high risk of another stroke, and there is need for improved strategies to predict recurrent stroke.

Objective  To assess the prognostic value of levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), N-terminal pro–B-type natriuretic peptide (NT-proBNP), C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size in patients with previous stroke or transient ischemic attack.

Design, Setting, and Participants  A nested case-control study of participants of the Perindopril Protection Against Recurrent Stroke Study was performed. The Perindopril Protection Against Recurrent Stroke Study was a placebo-controlled trial of a perindopril erbumine–based, blood pressure–lowering regimen that reduced ischemic stroke risk by 24% among individuals with previous stroke or transient ischemic attack. Each of 252 patients who experienced ischemic stroke during a mean follow-up of 3.9 years was matched to 1 to 3 control patients. Matching variables were age, sex, treatment allocated, region, and most recent qualifying event at randomization.

Main Outcome Measures  Risk of ischemic stroke predicted by baseline levels of sVCAM-1, NT-proBNP, C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size.

Results  Levels of sVCAM-1 and NT-proBNP predicted recurrent ischemic stroke. The odds ratio for patients in the highest, as compared with the lowest, quarter was 2.24 (95% confidence interval, 1.35-3.73) for sVCAM-1 level and 1.62 (95% confidence interval, 0.98-2.69) for NT-proBNP level, after adjustment for matching and other risk factors. Patients in the highest quarters for both sVCAM-1 and NT-proBNP levels had 3.6 times the risk of recurrent ischemic stroke compared with patients in the lowest quarters for both biologic markers. Level of sVCAM-1 was similarly predictive of ischemic stroke in patients allocated to placebo and perindopril-based therapy. Baseline plasma levels of C-reactive protein, homocysteine, renin, and lipids and lipoprotein particle concentration and size did not predict recurrent ischemic stroke risk.

Conclusion  Measurement of sVCAM-1 and NT-proBNP levels provides prognostic information for recurrent ischemic stroke beyond traditional risk factors.


Author Affiliations: St Vincent’s Institute of Medical Research, Fitzroy, Australia (Drs Campbell and Kemp); Department of Medicine, University of Melbourne, St Vincent’s Hospital, Fitzroy (Drs Campbell, Jenkins, and Kemp); CSIRO Health Sciences and Nutrition, Parkville, Australia (Dr Kemp); The George Institute for International Health, University of Sydney, Camperdown, Australia (Drs Woodward, Chalmers, Neal, Patel, and MacMahon, and Mr Colman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Activated Leukocyte Cell Adhesion Molecule and Prognosis in Acute Ischemic Stroke
Smedbakken et al.
Stroke 2011;42:2453-2458.
ABSTRACT | FULL TEXT  

Association of Circulating Inflammatory Markers With Recurrent Vascular Events After Stroke: A Prospective Cohort Study
Whiteley et al.
Stroke 2011;42:10-16.
ABSTRACT | FULL TEXT  

Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Goette et al.
Circulation 2008;117:732-742.
ABSTRACT | FULL TEXT  

Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease
Campbell et al.
European Journal of Cardiovascular Prevention & Rehabilitation 2007;14:413-418.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.